Literature DB >> 15122729

The independent statistician for data monitoring committees.

David L DeMets1, Thomas R Fleming.   

Abstract

Clinical trials are an essential part of the clinical research process. Recently, independent Data Monitoring Committees (DMCs) have been widely implemented to provide scientific and ethical oversight of pivotal clinical trials having irreversible outcomes such as death, stroke, disease recurrence or a serious adverse event. To carry out their responsibility, the DMC reviews interim analyses of accumulating data. We address the motivation for having the preparation and presentation of these interim analyses be conducted by an independent statistician who is not a member of the DMC and who is not the trial's lead or steering committee statistician. These views are based on having served as members of many DMCs as well as having been the independent statistician for several trials. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  2004        PMID: 15122729     DOI: 10.1002/sim.1786

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Experiences and challenges in data monitoring for clinical trials within an international tropical disease research network.

Authors:  M Chen-Mok; M J VanRaden; E S Higgs; R Dominik
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

2.  Data monitoring committees: Promoting best practices to address emerging challenges.

Authors:  Thomas R Fleming; David L DeMets; Matthew T Roe; Janet Wittes; Karim A Calis; Amit N Vora; Alan Meisel; Raymond P Bain; Marvin A Konstam; Michael J Pencina; David J Gordon; Kenneth W Mahaffey; Charles H Hennekens; James D Neaton; Gail D Pearson; Tomas Lg Andersson; Marc A Pfeffer; Susan S Ellenberg
Journal:  Clin Trials       Date:  2017-02-01       Impact factor: 2.486

Review 3.  Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?

Authors:  Susan S Ellenberg
Journal:  PLoS Med       Date:  2012-06-12       Impact factor: 11.069

4.  Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study.

Authors:  Rickey E Carter; Susan C Sonne; Kathleen T Brady
Journal:  BMC Med Res Methodol       Date:  2005-03-30       Impact factor: 4.615

Review 5.  Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.

Authors:  Victoria Borg Debono; Lawrence Mbuagbaw; Lehana Thabane
Journal:  Trials       Date:  2017-03-09       Impact factor: 2.279

6.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

Review 7.  Factors influencing the statistical planning, design, conduct, analysis and reporting of trials in health care: A systematic review.

Authors:  Marina Zaki; Lydia O'Sullivan; Declan Devane; Ricardo Segurado; Eilish McAuliffe
Journal:  Contemp Clin Trials Commun       Date:  2022-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.